In the bio-tech market,
ONEOK, Inc. (OKE) has been subject to a flurry of financial action.
Royal Bank Of Canada has reduced its price target for OKE to $94.00. Amid volatile market conditions, the outlook for
Oneok is mixed, with cautious technical signs and mixed analyst views.
Raymond James has downgraded its price target for ONEOK yet maintains an Overweight rating. In anticipation of Q2 earnings, investors are advised on ways to earn from ONEOK. The company announced higher Q1 2025 earnings and has affirmed its 2025 financial guidance. Several companies including
EagleClaw Capital Management LLC, Mackenzie Financial Corp and Mediolanum International Funds Ltd have made significant investments in OKE, highlighting increased interest. Following a market slump, OKE's stock value ascended and surged. The company secured the remaining interest in Delaware Basin JV and celebrated the completion of the strategic EnLink Midstream acquisition. Amid these developments, market analysts suggest OKE could surge by 28.58%. Moving forward, OKE maintains a strong annual dividend of $4.12 and has acquired Joint Ventures with MPLX.
Oneok OKE News Analytics from Tue, 29 Oct 2024 07:00:00 GMT to Sat, 02 Aug 2025 17:18:49 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -1
